Skip to main content
. 2024 Oct 4;10(40):eadn8760. doi: 10.1126/sciadv.adn8760

Fig. 5. EC-pericyte interactions are altered in ischemic limbs of TrailEC−/− mice.

Fig. 5.

(A) Hbegf and Lamc1 mRNA levels in ECs isolated from Trail+/+ and Trail−/− mice (n = 4 to 7 per genotype). (B) mRNA expression of Hbegf receptors Erbb2 and Egfr, and Lamc1 receptors Itgα1 and Itgb1 in gastrocnemius muscle from TrailEC+/+ and TrailEC−/− mice (n = 5 to 8 per genotype). (C) Erbb2 and Egfr expression in primary murine pericytes. (D) mRNA expression of Hbegf receptors Erbb2 and Egfr in nonischemic and ischemic skeletal muscle from patients with PAD (n = 5). (E) Stable microvessel numbers in gastrocnemius muscle of TrailEC−/− mice treated with vehicle or recombinant murine HBEGF and 14 days after HLI (n = 6 to 7 per treatment). (F) Laser Doppler imaging showing blood perfusion over time in TrailEC−/− mice treated with vehicle or recombinant HBEGF (1 μg I.M., 2 days before surgery, day of surgery, and then daily). Top: Representative image of blood flow at 14 days. Bottom: Quantification (n = 6 to 7 per treatment). (G) Recombinant human HBEGF increases eNOS expression and phosphorylation (p-eNOS) in HMEC-1. β-Actin demonstrates unbiased loading. All mRNA expression was normalized to β-actin. Student’s t test, paired t test, or two-way ANOVA; *P < 0.05 and ***P < 0.001.